7xm site
Southern California defense contractors optimistic Trump administration could create jobs locallyChinatown businesses concerned over plan to open HART hub
This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here . > 24/7 San Diego news stream: Watch NBC 7 free wherever you are Nvidia shares fall after China opens investigation Shares of artificial intelligence darling Nvidia were under pressure after a regulator in China said it was investigating the chipmaker over possible violations of the country's antimonopoly law. This investigation was in relation to Nvidia's 2020 acquisition of Israeli firm Mellanox and some agreements made during the acquisition, the Chinese government said Monday. 26-year-old detained by police in connection with fatal shooting of UnitedHealthcare CEO University of Pennsylvania graduate Luigi Mangione was detained by police as a "strong person of interest" in the killing of UnitedHealthcare CEO Brian Thompson after police found him carrying a pistol, a silencer, a mask and fake identification cards. Mangione had in his possession a suspected "ghost gun" — which lacks a serial member — capable of firing 9 mm rounds, authorities said. China trade in November misses expectations China's exports and imports both missed expectations in November, fueling worries over the health of the Chinese economy. Exports rose 6.7% in U.S. dollar terms from a year ago, sharply lower than the 12.7% growth in the previous month and missing forecasts of a 8.5% rise. Import data surprised with a decline of 3.9%, compared to a 0.3% rise expected by economists. Most Asia markets gain, breaking ranks with Wall Street Most markets rose in Asia , shrugging off the weaker close overnight on Wall Street. South Korea's Kospi led gains, rising 2.4%. The S&P 500 and Nasdaq Composite pulled back from record highs Monday, with tech shares lagging. The tech-heavy Nasdaq shed 0.62%, while the S&P fell 0.61%. The Dow Jones Industrial Average declined by 0.54%. [PRO] Investing in mid-caps may be the way to go in 2025 Mid-cap stocks could be the sweet spot for investors in 2025, having been outperforming recently. Many investors expect further gains for mid-caps, which offer better quality businesses than small-caps, as well as stronger growth prospects than large-caps. Money Report ‘White gold' seen as pivotal to Europe's massive trade deal with South America Is this London's best kept cultural secret? A royal palace turned parking lot is reinventing itself — again Technology stocks have underpinned the impressive rally in US stocks this year. But they are not immune from the laws of gravity. Monday's session saw large technology stocks underperform the broader market. Oracle missed forecasts and AMD was downgraded by Bank of America . But perhaps the biggest news of the day concerned Nvidia, whose shares have surged an astounding 188% this year. China's State Administration for Market Regulation opened an investigation into the chipmaker in relation to the acquisition of Mellanox and some agreements made during the acquisition. The news prompted Nvidia's shares to fall 2.6% overnight. The development suggests that while the year is ending, the fight for tech dominance around the world may just be intensifying. Competition between the U.S. and China over chipmaking is rising, with the Biden administration on Dec. 2 announcing a slew of curbs targeting semiconductor toolmakers. China then retaliated by banning exports of critical minerals such as gallium, and on the same day, four of the country's top industry associations said Chinese companies should be wary of buying U.S. chips as they were "no longer safe" and buy locally instead. Previous trade skirmishes have centered on areas such as metals, farm products, and automobiles. With a tougher stance on China expected from the incoming Trump administration, could the next trade war instead be focused around chips, which arguably have permeated every facet of our lives? — CNBC's Samantha Subin contributed to this report. Also on CNBC Tech firms in the spotlight Political uncertainty intensifies over the weekend Global political uncertainty intensifies over the weekendSAN ANTONIO , Nov. 22, 2024 /PRNewswire/ -- The 2025 Hyundai Santa Cruz XRT has been named the Compact Truck of Texas at the Texas Auto Writers Association (TAWA) annual Truck Rodeo held Sept. 26-27, 2024 . The TAWA Texas Truck Rodeo is a prominent annual event where top automotive media evaluate new vehicles based on performance, value, and overall appeal. Competing against strong contenders, the updated 2025 Santa Cruz XRT impressed judges with its rugged design, advanced technology, and enhanced off-road capability. "We are thrilled to see the 2025 Hyundai Santa Cruz XRT recognized as the 'Compact Truck of Texas .' This award reflects our commitment to offering customers a versatile, fun-to-drive vehicle that is not only capable off-road but also packed with cutting-edge technology and design," said Ricky Lao , director of product planning, Hyundai Motor North America. "The Santa Cruz XRT brings together rugged capability with advanced safety features, making it the perfect choice for adventure-minded consumers seeking the best of both worlds." "The Texas Truck Rodeo is a premier event where vehicles are put to the test by seasoned automotive journalists, and the competition this year was fierce. The 2025 Hyundai Santa Cruz XRT stood out for its impressive blend of rugged off-road capability, cutting-edge technology, and unique design," said Cory Fourniquet , president, Texas Auto Writers Association. "This recognition as the 'Compact Truck of Texas' is well-deserved and highlights Hyundai's commitment to delivering versatile and innovative vehicles that meet the needs of Texas drivers." The 2025 Santa Cruz XRT, featuring a new aggressive front design, XRT-exclusive enhancements including front tow hooks, all-terrain tires, and wrench-inspired wheels, sets a new standard. The model's updated interior boasts a panoramic curved display with an available 12.3-inch driver information cluster and infotainment touchscreen display, alongside standard wireless Apple CarPlay® and Android AutoTM, providing an intuitivedriving experience. Hyundai Motor America Hyundai Motor America offers U.S. consumers a technology-rich lineup of cars, SUVs, and electrified vehicles, while supporting Hyundai Motor Company's Progress for Humanity vision. Hyundai has significant operations in the U.S., including its North American headquarters in California , the Hyundai Motor Manufacturing Alabama assembly plant, the all-new Hyundai Motor Group Metaplant America, and several cutting-edge R&D facilities. These operations, combined with those of Hyundai's 835 independent dealers, contribute $20.1 billion annually and 190,000 jobs to the U.S. economy, according to a recent economic impact report . For more information, visit www.hyundainews.com . Hyundai Motor America on Twitter | YouTube | Facebook | Instagram | LinkedIn | TikTok View original content to download multimedia: https://www.prnewswire.com/news-releases/2025-hyundai-santa-cruz-xrt-named-compact-truck-of-texas-at-texas-auto-writers-associations-truck-rodeo-302314024.html SOURCE Hyundai
Qatar's prime minister said on Saturday that momentum had returned to talks aimed at securing a truce and hostage exchange deal in Gaza following Donald Trump's election as US president. The Gulf emirate, along with the United States and Egypt, had been involved in months of unsuccessful negotiations for a Gaza truce and hostage release. But in November, Doha announced it had put its mediation on hold, saying it would resume when Hamas and Israel showed "willingness and seriousness". "We have sensed, after the election, that the momentum is coming back," Sheikh Mohammed bin Abdulrahman bin Jassim Al-Thani told the Doha Forum for political dialogue. He spoke as a source close to the Hamas delegation in the talks told AFP that a new round of negotiations will "most likely" begin in the coming week. Sheikh Mohammed said that while there were "some differences" in the approach to an agreement by the outgoing and incoming US administrations, "we didn't see or recognise any disagreement on the goal itself to end the war". He said there had been "a lot of encouragement from the incoming administration in order to achieve a deal, even before the president comes to the office", adding this had affected Qatar's decision to get talks "back on track". "We hope to get things done as soon as possible. We hope that the willingness of the parties to engage in a good faith continues," he said. The source close to the Hamas delegation, speaking on condition of anonymity, told AFP: "Based on contacts with the mediators, we expect a new round of negotiations to begin in Cairo, most likely this week, to discuss ideas and proposals regarding a ceasefire and a prisoner exchange." The source added that Turkey, as well as Egypt and Qatar, had been "making commendable efforts to stop the war". In a statement later on Saturday, the group said Turkish spy chief Ibrahim Kalin met with a Hamas delegation in Doha to discuss the war in Gaza. The war in Gaza was sparked by Hamas's October 7, 2023 attack on Israel, which resulted in the deaths of 1,208 people, mostly civilians, according to an AFP tally based on official figures. During the attack, militants kidnapped 251 people, 96 of whom remain in Gaza, including 34 declared dead by the Israeli military. Israel's retaliatory military campaign in Gaza has killed at least 44,664 people, a majority civilians, according to figures from the territory's Hamas-run health ministry which the UN considers reliable. The US president-elect this week warned on social media of unspecified massive repercussions if the hostages were not released by the time he takes office next month. Trump has vowed staunch support for Israel and to dispense with outgoing President Joe Biden's occasional criticism, but has also spoken of his desire to secure deals on the world stage. On Saturday, Qatar's premier dismissed the prospect of his country facing greater pressure over the status of the Hamas political bureau, which the Gulf state has hosted since 2012 with Washington's blessing. Sheikh Mohammed called the Hamas office a "platform to convene between the different parties". Qatar was not "expected to enforce solutions" on the Palestinian militants, he added. csp/srm/dcp/itGERMANTOWN, Tenn. , Dec. 10, 2024 /PRNewswire/ -- Mid-America Apartment Communities, Inc., or MAA (NYSE: MAA), today announced that its board of directors approved a quarterly dividend payment of $1.515 per share of common stock to be paid on January 31, 2025 , to shareholders of record on January 15, 2025 .
RG-6641 is a synthetic peptide commercialized by Roche, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 was terminated. Smarter leaders trust GlobalData The gold standard of business intelligence. The revenue for RG-6641 is expected to reach an annual total of $32 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. RG-6641 Overview CT-868 (RG6641) is under development for the treatment of type-2 diabetes, type 1 diabetes, and obesity. It is administered though subcutaneous route in the form of solution. The drug candidate acts by targeting glucagon like peptide1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide/gastric inhibitory polypeptide receptor (GIP-R). It is being developed based on chemotype evolution technology. It was also under development for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Roche Overview Roche is a holding company that is involved in the business of offering oncology, immunology, infectious diseases, ophthalmology and neuroscience research services. The company is headquartered in Basel, Basel-Stadt, Switzerland. The company reported revenues of (Swiss Francs) CHF58,716 million for the fiscal year ended December 2023 (FY2023), a decrease of 7.2% over FY2022. In FY2023, the company’s operating margin was 25.8%, compared to an operating margin of 27.5% in FY2022. In FY2023, the company recorded a net margin of 19.6%, compared to a net margin of 19.6% in FY2022. For a complete picture of RG-6641’s valuation, From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company. The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s .
Key details about the man accused of killing of UnitedHealthcare's CEOTHOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen
However, the N-Dubz star has since left the jungle following a public vote but viewers of the show are shocked at her actions since. Before heading into the Australian jungle, celebrities often share pictures of themselves in their camp uniforms and the ITV show also shares videos and images of them while they’re in there which they share to their own personal accounts. However, viewers noticed the lack of Instagram posts about Tulisa’s time in the jungle following her exit. A post shared by I'm a Celebrity... (@imacelebrity) Taking to X, formerly Twitter, fans of the show noticed the singer has deleted her posts about the ITV show and her involvement. After leaving the show, Tulisa would’ve been given her phone back so it’s likely she deleted the posts herself. One viewer said: “Why has Tulisa deleted everything from her socials in relation to #ImACeleb”. (function (d, s, n) { var js, fjs = d.getElementsByTagName(s)[0]; js = d.createElement(s); js.className = n; js.src = "//player.ex.co/player/d13dbc37-e6fb-4c19-a782-153b431671ea"; fjs.parentNode.insertBefore(js, fjs); js.setAttribute('programmatic', 'true'); js.onload = function () { const playerApi237931 = ExCoPlayer.connect('d13dbc37-e6fb-4c19-a782-153b431671ea'); playerApi237931.init({ "autoPlay": false, "mute": true, "showAds": true, "playbackMode": "play-in-view", "content": { "playFirst": [ { "title": "How much is Ant and Dec's net worth?", "src": "https://large-cdn.ex.co/transformations/production/3dac3c05-257d-45d2-b760-c1524f8b72f3/720p.mp4" } ] }, "sticky": { "mode": "persistent", "closeButton": true, "pauseOnClose": true, "desktop": { "enabled": false, "position": "bottom-right" }, "mobile": { "enabled": false, "position": "upper-small" } }}); }; }(document, 'script', 'exco-player')); Another commented: “Why has Tulisa deleted all traces of I’m a celeb off her socials?” A third called the singer out, saying: “So grateful you delete all trace of I’m a Celeb on your Instagram ey Tulisa?” After public votes, three celebrities have been eliminated from the ITV show so far. Loose Women star Jane Moore was the first to leave while Dean McCullough, a BBC Radio 1 presenter, was the second to be reunited with loved ones. Recommended reading: N-Dubz star Tulisa was the third to leave the jungle and said: “It is tough in there, leaving is still a happy thing.” Speaking about her I'm A Celebrity experience, she added: “I just think you're more grateful for everything, the food you eat, being around the people you love, the home comforts, just makes you very appreciative of life.” Tonight (December 3), another celebrity will leave the jungle. I’m A Celebrity... Get Me Out Of Here! continues nightly at 9pm on ITV1, STV and ITVX.Eagle-eyed viewers spot Tulisa was eager to remove 'all traces' of I'm A Celeb
Apple's Investment in the UK Exceeds £18 Billion